Histomorphometry revealed that the decrease of the progression rate of atherosclerotic lesions in the Empagliflozin-treated mice group was nearly statistically significant, and the lumen area expanded by approximately 50%.
1
—
—
Histomorphometry revealed that the decrease of the progression rate of atherosclerotic lesions in the Empagliflozin-treated mice group was nearly statistically significant, and the lumen area expanded by approximately 50%.